Retatrutide Explained: How It Works, What the Research Shows, and What Patients Should Know
Retatrutide is an investigational medication being studied for obesity, overweight, and type 2 diabetes. It is administered once weekly and is designed to activate three hormone receptors:
- Glucose-dependent insulinotropic polypeptide, or GIP
- Glucagon-like peptide-1, or GLP-1
- Glucagon
This combination has made retatrutide one of the most closely watched medications in metabolic medicine. The early research is promising, but it is not a miracle drug, and the available evidence does not establish that it will be the right treatment for every patient.
What is retatrutide?
Retatrutide, also known by the development name LY3437943, is a once-weekly triple receptor agonist. Unlike medications that act on one pathway, or dual agonists that act on two, retatrutide is designed to influence three interconnected metabolic signals.
The scientific interest comes from the possibility of addressing several aspects of weight regulation at once:
- Appetite and food intake
- Glucose regulation
- Insulin response
- Fat metabolism
- Energy expenditure
These effects are being studied in controlled clinical trials. They should not be interpreted as a guarantee of a particular amount of weight loss or as evidence that retatrutide is superior for every individual.
How the three pathways may work together
GLP-1
GLP-1 receptor activity is associated with increased satiety, reduced appetite, and improved glucose-dependent insulin secretion. GLP-1-based treatments may also slow gastric emptying, although the degree and clinical relevance can vary between medications and individuals.
For patients using approved GLP-1 therapies, these effects can make it easier to reduce food intake while supporting blood sugar management.
GIP
GIP is another incretin hormone involved in the body’s response to food. GIP receptor activity may enhance insulin secretion and complement GLP-1 signaling. Researchers are studying whether the combination can improve glucose control and weight reduction beyond what may be achieved through one pathway alone.
The role of GIP is more complex than simply “increasing metabolism.” Its effects may depend on the medication, dosage, tissue involved, and the patient’s metabolic health.
Glucagon
Glucagon has effects that differ from GLP-1 and GIP. It can promote the mobilization of stored energy and may increase energy expenditure. However, glucagon can also raise blood glucose. Retatrutide is designed to combine glucagon activity with GLP-1 and GIP activity, which may help balance these effects.
This is one of the central scientific questions surrounding the medication: whether the combined pathways can support meaningful weight loss while maintaining acceptable glucose control and tolerability.
What the obesity research found
The most widely cited obesity study was a phase 2, randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2023.
The study included 338 adults with obesity, or overweight accompanied by at least one weight-related condition. Participants received different once-weekly doses of retatrutide or placebo for 48 weeks.
At 48 weeks, the researchers reported the following least-squares mean changes in body weight:
- 1 mg: 8.7% reduction
- Combined 4 mg groups: 17.1% reduction
- Combined 8 mg groups: 22.8% reduction
- 12 mg: 24.2% reduction
- Placebo: 2.1% reduction
The results were dose-dependent, meaning that higher doses were generally associated with greater average weight reduction in this study. However, study averages do not predict an individual patient’s outcome.
The trial also examined how many participants reached at least 5%, 10%, or 15% weight reduction. At the highest dose, 100% of participants reached at least 5%, 93% reached at least 10%, and 83% reached at least 15% at 48 weeks.
These findings are notable, but they came from a phase 2 study with a limited number of participants and a relatively short follow-up period. They do not answer every question about long-term safety, weight maintenance, or cardiovascular health.
Read the full peer-reviewed article:
- Jastreboff et al., New England Journal of Medicine, 2023
- PubMed record for the obesity trial
- DOI: 10.1056/NEJMoa2301972
What the type 2 diabetes research found
A separate phase 2 trial evaluated retatrutide in adults with type 2 diabetes. The study included 281 participants and compared several retatrutide doses with placebo and dulaglutide, an approved GLP-1 receptor agonist.
At 24 weeks, the 12 mg retatrutide group had an average HbA1c reduction of approximately 2.02 percentage points, compared with approximately 0.01 percentage points with placebo. At 36 weeks, body weight decreased by approximately 16.94% in the 12 mg group, compared with approximately 3.00% with placebo.
The results were dose-dependent and varied across treatment groups. The study was not designed to establish long-term cardiovascular benefit or to determine whether retatrutide should replace currently approved diabetes treatments.
Read the full peer-reviewed article:
Side effects and tolerability
Gastrointestinal symptoms were the most frequently reported adverse effects in both phase 2 studies. These included:
- Nausea
- Diarrhea
- Vomiting
- Constipation
In the obesity trial, gastrointestinal effects were generally mild to moderate, dose-related, and more common at higher doses. The researchers also reported that a lower starting dose helped reduce gastrointestinal symptoms.
In the type 2 diabetes trial, mild-to-moderate gastrointestinal adverse events occurred in 35% of participants receiving retatrutide, compared with 13% in the placebo group. The frequency varied by dose and escalation schedule.
These effects matter because reduced appetite can sometimes make it difficult to consume enough protein, fluids, fiber, and other nutrients. Anyone using a medically supervised weight-loss treatment should discuss nutrition, hydration, bowel changes, and persistent nausea or vomiting with a qualified clinician.
Heart-rate observations
The obesity trial reported dose-dependent increases in heart rate. Heart rate reached its highest point around 24 weeks and then declined thereafter.
This finding requires continued study. A short-term change in heart rate does not establish whether a treatment improves or worsens long-term cardiovascular health. Retatrutide’s cardiovascular effects cannot be assumed from weight-loss results alone.
Long-term cardiovascular outcomes, including effects on heart attack, stroke, heart failure, and cardiovascular death, require dedicated outcome studies and longer follow-up.
What remains unknown
Retatrutide’s early results are significant, but several important questions remain:
- How durable is the weight loss after treatment is reduced or stopped?
- How much lean mass is preserved during weight loss?
- What are the long-term risks and benefits?
- How does retatrutide compare with approved GLP-1 and GIP/GLP-1 medications in larger, longer trials?
- What are the cardiovascular outcomes?
- How should it be used in older adults or people with kidney, liver, gastrointestinal, or cardiovascular conditions?
- What is the appropriate role of nutrition and resistance training during treatment?
- Which patients are most likely to benefit or experience intolerable side effects?
Phase 3 trials are intended to provide broader safety and efficacy information. The official ClinicalTrials.gov record for TRIUMPH-1, NCT05929066, lists the study as completed and, as of the record update posted August 21, 2026, indicates that results had not yet been posted. A registry listing is a research-status source; it is not the same as a peer-reviewed publication.
Approval and availability
Retatrutide is investigational. It is not an FDA-approved medication for weight loss, obesity, type 2 diabetes, or another condition at the time of this article.
Approval status, pharmacy access, and regulatory requirements can change, so patients should verify current information through the FDA’s official labeling and drug databases and through the prescribing practice’s medical oversight. Maison Jolie Aesthetics may offer or coordinate access to retatrutide through a compounding pharmacy under medical-director oversight, when clinically appropriate and legally permitted, subject to patient eligibility and current pharmacy and regulatory requirements.
Patients should not purchase or self-administer retatrutide marketed online as a “research peptide.” Compounded retatrutide products are not FDA-approved, and product quality, formulation, labeling, and availability can vary. If prescribed, they should be used only through the practice’s medical oversight and an appropriately licensed pharmacy, with attention to identity, concentration, storage, dosing, monitoring, and follow-up.
A considered approach to weight management
Retatrutide may become an important future treatment, but the current evidence should be read with precision. Phase 2 trials show substantial average weight loss and meaningful improvements in glycemic measures. They also show gastrointestinal adverse effects and heart-rate changes. Long-term safety, durability, cardiovascular outcomes, and real-world effectiveness still require further evidence.
For individuals considering GLP-1 or other medically supervised weight-loss treatments, a consultation should include medical history, current medications, nutrition, laboratory evaluation when appropriate, treatment goals, and a discussion of approved options. For retatrutide specifically, patients should discuss investigational status, risks, benefits, alternatives, informed consent, dosing, monitoring, and follow-up with the medical director.
Maison Jolie Aesthetics offers a personalized setting for conversations about aesthetic and wellness goals. Learn more about Maison Jolie Aesthetics, explore our services, or schedule a consultation.
Medical disclaimer
This article is for educational purposes only and does not diagnose, treat, or prevent any medical condition. It is not a substitute for medical advice, evaluation, or treatment from a qualified healthcare professional. Retatrutide is investigational and is not FDA-approved. Any consideration of compounded retatrutide should occur only under appropriate medical guidance, with prescribing oversight, patient-specific evaluation, and use of an appropriately licensed pharmacy when legally permitted. Always verify current approval status, labeling, availability, risks, and treatment eligibility with a licensed clinician.